The aims of the study were a) to identify the early manifestations of RE that can prompt an early and reasonably secure diagnosis and an early targeted therapy; b) to evaluate the efficacy of different medical and surgical therapies; c) to verify the diagnostic value of GluR3 antibodies. We reviewed the clinical, MRI and EEG features present at the onset in twelve patients with istologically proven RE, and the response to medical and surgical treatment in 16 cases. Furthermore, we evaluated the presence of anti-GluR3 antibodies in 11 RE patients, and in a control group. Our data demonstrate that a) the association of partial seizures, with focal EEG and MRI changes allow a tentative diagnosis of RE 4-6 months from first symptoms. The diagnosis can be confirmed in 9-12 months by neurologic deterioration and worsening of the MRI picture; b) although surgical therapy remains inevitable in the most cases, medical therapies (including steroids, immunoglobuline, and plasma exchange) can produce significant, albeit transient, effects and should be considered in selected patients; c) the presence of anti-GluR3 antibodies cannot be considered a marker for diagnosis, as it is not able to distinguish between RE and other forms of epilepsy.
|Translated title of the contribution||Rasmussen encephalitis: Results of LICE collaborative study on the definition of diagnostic criteria and therapy|
|Number of pages||4|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - Oct 2002|
ASJC Scopus subject areas
- Clinical Neurology